布鲁顿酪氨酸激酶抑制剂治疗B细胞恶性肿瘤中国专家共识  

Consensus of Chinese experts on Bruton tyrosine kinase inhibitors in treatment of B-cell malignant tumors

作　　者：中国临床肿瘤学会(CSCO)淋巴瘤专家委员会 马军[2] Lymphoma Expert Committee of Chinese Society of Clinical Oncology(CSCO);Ma Jun(不详;Harbin Institute of Hematology and Oncology,Harbin 150010,China)

机构地区：[1]不详 [2]哈尔滨血液病肿瘤研究所,哈尔滨150010

出　　处：《白血病．淋巴瘤》2022年第9期513-526,共14页Journal of Leukemia & Lymphoma

摘　　要：近年来,针对肿瘤细胞内异常信号特异性发挥作用的靶向药物为肿瘤治疗提供了更多选择。B细胞受体(BCR)信号通路的过度活化或异常与慢性淋巴细胞白血病/小淋巴细胞淋巴瘤、套细胞淋巴瘤等多种B细胞恶性肿瘤的发生、发展密切相关。布鲁顿酪氨酸激酶(BTK)是B细胞发育过程中关键的效应分子,涉及细胞增殖、成熟、分化、凋亡和迁移,为BCR通路的关键激酶,抑制其活性可产生明显的抗肿瘤效应。目前已研发上市的BTK抑制剂包括伊布替尼、泽布替尼、奥布替尼、阿卡替尼等。为了进一步优化BTK抑制剂在B细胞恶性肿瘤治疗中的临床应用,共识专家组根据目前国内BTK抑制剂应用现状,结合国内外最新的权威指南及循证医学证据,制定了BTK抑制剂治疗B细胞恶性肿瘤中国专家共识。In recent years,targeted drugs that specifically disturb abnormal signals in tumor cells have provided more treatment options for patients.The over activation or abnormality of B-cell receptor(BCR)signaling pathway is closely related to the occurrence and development of a variety of B-cell malignant tumors,such as chronic lymphocytic leukemia/small lymphocytic lymphoma,mantle cell lymphoma,etc.Bruton tyrosine kinase(BTK)is a key effector molecule in the development of B cells involving in cell proliferation,maturation,differentiation,apoptosis and migration.As a crucial kinase in BCR pathway,inhibiting the activity of BTK can produce obvious antitumor effect.BTK inhibitors that have been developed and launched in recent years include ibrutinib,zanubrutinib,orelabrutinib,acalabrutinib,etc.In order to optimize the clinical practice of BTK inhibitors in the treatment of B-cell malignant tumors,based on the current domestic application status of BTK inhibitors combined with the latest authoritative guidelines and the evidence-based medical evidence at home and abroad,the consensus expert group formulated the Chinese expert consensus on BTK in the treatment of B-cell malignant tumors.

关 键 词：血液肿瘤 B淋巴细胞 布鲁顿酪氨酸激酶 蛋白激酶抑制剂 分子靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]